Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ancillary risk information and pharmacogenetic tests: social and policy implications.

The pharmacogenomics journal - 1 Apr 2008

Henrikson N B, Burke W, Veenstra D L

Abstract excerpt

Some pharmacogenetic tests may provide ancillary disease risk information. To evaluate evidence and assess the social and policy implications of ancillary disease risk information associated with candidate pharmacogenetic variants, We conducted a literature search and abstract review of disease susceptibility studies for each of 42 gene variants potentially associated with drug response. Twenty-two variants (53%)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Genetic Privacy
Share to Health Knowledge, Attitudes, Practice

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Health Policy

Share to Incidental Findings

Share to Patient Education as Topic

Share to Patient Selection

Share to Pharmacokinetics

Source

Identifiers

PMID: 17486108
DOI: 10.1038/sj.tpj.6500457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ancillary risk information and pharmacogenetic tests: social and policy implications.PMID 17486108Read ↗

The potential social impact of predictive genetic testing for susceptibility to common chronic diseases: a review and proposed research agenda.Semantic proximity Read ↗

Pharmacogenetic testing: not as simple as it seems.Semantic proximity Read ↗

Public Perspectives About Pharmacogenetic Testing and Managing Ancillary FindingsSemantic proximity Read ↗

Genetic testing for disease susceptibilities: consequences for genetic counseling.Semantic proximity Read ↗

Genetic test evaluation: information needs of clinicians, policy makers, and the public.Semantic proximity Read ↗

Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMeSemantic proximity Read ↗

Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.Semantic proximity Read ↗

Pharmacogenomic incidental findings in 308 families: The NIH Undiagnosed Diseases Program experience.Semantic proximity Read ↗

Implications of the incidentalome for clinical pharmacogenomics.Semantic proximity Read ↗

Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.Semantic proximity Read ↗

The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors?Semantic proximity Read ↗

A critical appraisal of pharmacogenetic inference.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.